Results 221 to 230 of about 790,096 (261)
Some of the next articles are maybe not open access.
Ranibizumab biosimilar (Oceva) – real-world experience from India (RORE study)
Expert Opinion on Biological TherapyBackground To evaluate early real-world clinical outcomes on the safety and efficacy of the ranibizumab biosimilar (Oceva, Sun Pharmaceuticals, India). Research design and methods A multicenter, retrospective, uncontrolled observational study evaluating ...
Ashish Sharma +5 more
semanticscholar +1 more source
Pharmazie, 2020
Biosimilar products of filgrastim have become available for improved sustainability of cancer care; however, the real-world safety profile remains unknown.
Iku Niinomi +5 more
semanticscholar +1 more source
Biosimilar products of filgrastim have become available for improved sustainability of cancer care; however, the real-world safety profile remains unknown.
Iku Niinomi +5 more
semanticscholar +1 more source
Generics and Biosimilars Initiative Journal, 2021
At the beginning of the COVID-19 pandemic, Ecuador was unprepared for the overwhelming number of COVID-19 cases. As the general population started to see the eff ects of the pandemic, unproven treatments and medications were sought by the population to try to ameliorate the impact of the pandemic.
Esteban Ortiz-Prado +5 more
openaire +1 more source
At the beginning of the COVID-19 pandemic, Ecuador was unprepared for the overwhelming number of COVID-19 cases. As the general population started to see the eff ects of the pandemic, unproven treatments and medications were sought by the population to try to ameliorate the impact of the pandemic.
Esteban Ortiz-Prado +5 more
openaire +1 more source
Drug Testing and Analysis, 2019
The ongoing shift from small molecule drugs to protein therapeutics in the pharmaceuticals industry presents a considerable challenge to generic drug developers who are increasingly required to demonstrate biosimilarity for biological macromolecules, a ...
Kerene A Brown +3 more
semanticscholar +1 more source
The ongoing shift from small molecule drugs to protein therapeutics in the pharmaceuticals industry presents a considerable challenge to generic drug developers who are increasingly required to demonstrate biosimilarity for biological macromolecules, a ...
Kerene A Brown +3 more
semanticscholar +1 more source
Analytical comparison of Soliris® and its biosimilar, PRK-001
, 2020Soliris® (Eculizumab) was approved by regulatory authorities as the first drag for treatment of orphan disease, paroxysmal nocturnal hemoglobinuria, in 2007.
M. A. Zhuchenko +8 more
semanticscholar +1 more source
2022
More specifically, this thesis examines the information exchange between originator manufacturers and biosimilar manufacturers related to patents and data exclusivity, and how the information exchange affects biosimilars and biosimilar development.
openaire +1 more source
More specifically, this thesis examines the information exchange between originator manufacturers and biosimilar manufacturers related to patents and data exclusivity, and how the information exchange affects biosimilars and biosimilar development.
openaire +1 more source
Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
2014223 ...
openaire +1 more source
Journal of European Economic History
The global pharmaceutical industry has undergone a paradigm shift from the dominance of blockbuster small-molecule drugs to biologics and biosimilars. This transformation is driven by patent expirations, escalating research and development (R&D) costs, advancements in biotechnology, and the increasing burden of chronic diseases.
openaire +1 more source
The global pharmaceutical industry has undergone a paradigm shift from the dominance of blockbuster small-molecule drugs to biologics and biosimilars. This transformation is driven by patent expirations, escalating research and development (R&D) costs, advancements in biotechnology, and the increasing burden of chronic diseases.
openaire +1 more source